ENvue Medical (FRA:56R1) Cyclically Adjusted Revenue per Share: €356.84 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:56R1 ENvue Medical Inc FRA:56R1
37 GF Score
Price €6.20
GF Value €72.47
! 4 Warning Signs
View Full Analysis

What is ENvue Medical Cyclically Adjusted Revenue per Share?

ENvue Medical FRA:56R1 37 Cyclically Adjusted Revenue per Share is €356.84 as of Mar. 2026. GuruFocus rates FRA:56R1 with a GF Score™ of 37/100 and a GF Value™ of €72.47. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ENvue Medical's adjusted revenue per share for the three months ended in Mar. 2026 was €0.172. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €356.84 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ENvue Medical's average Cyclically Adjusted Revenue Growth Rate was -4.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ENvue Medical was -3.60% per year. The lowest was -3.60% per year. And the median was -3.60% per year.

As of today (2026-08-19), ENvue Medical's current stock price is €6.20. ENvue Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €356.84. ENvue Medical's Cyclically Adjusted PS Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ENvue Medical was 6.34. The lowest was 0.01. And the median was 0.52.


ENvue Medical  (FRA:56R1) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ENvue Medical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=6.20/356.84
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ENvue Medical was 6.34. The lowest was 0.01. And the median was 0.52.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ENvue Medical Cyclically Adjusted Revenue per Share Related Terms


ENvue Medical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ENvue Medical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENvue Medical Cyclically Adjusted Revenue per Share Chart

ENvue Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 13.44 71.96 128.84 371.17

ENvue Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 244.54 128.70 155.27 371.17 356.84

FRA:56R1 vs BTCY, VYCO, ADMT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, ENvue Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENvue Medical Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ENvue Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ENvue Medical's Cyclically Adjusted PS Ratio falls into.


FRA:56R1
37GF Score
ENvue Medical Inc FRA:56R1
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ENvue Medical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ENvue Medical's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.172/330.2130*330.2130
=0.172

Current CPI (Mar. 2026) = 330.2130.

ENvue Medical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 27.500 241.018 37.677
201609 27.000 241.428 36.929
201612 23.000 241.432 31.458
201703 24.500 243.801 33.184
201706 23.000 244.955 31.005
201709 27.500 246.819 36.792
201712 19.667 246.524 26.343
201803 20.667 249.554 27.347
201806 37.667 251.989 49.360
201809 15.333 252.439 20.057
201812 15.667 251.233 20.592
201903 23.333 254.202 30.310
201906 77.667 256.143 100.126
201909 30.667 256.759 39.440
201912 26.000 256.974 33.410
202003 34.333 258.115 43.923
202006 79.667 257.797 102.046
202009 31.750 260.280 40.281
202012 7.400 260.474 9.381
202103 7.909 264.877 9.860
202106 24.000 271.696 29.169
202109 35.333 274.310 42.534
202112 57.167 278.802 67.709
202203 19.000 287.504 21.822
202206 35.308 296.311 39.348
202209 7.538 296.808 8.386
202212 -7.385 296.797 -8.216
202303 22.067 301.836 24.142
202306 18.067 305.109 19.554
202309 26.813 307.789 28.766
202312 59.944 306.746 64.530
202403 33.880 312.332 35.820
202406 30.360 314.175 31.910
202409 13.560 315.301 14.201
202412 12.471 315.605 13.048
202503 15.048 319.799 15.538
202506 8.917 322.561 9.129
202509 0.717 324.800 0.729
202512 0.242 324.054 0.247
202603 0.172 330.213 0.172

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €356.84 mean?
ENvue Medical (FRA:56R1) has a Cyclically Adjusted Revenue per Share of €356.84 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ENvue Medical and its competitors.
Is ENvue Medical's Cyclically Adjusted Revenue per Share too high?
ENvue Medical's current Cyclically Adjusted Revenue per Share is €356.84. Overall, ENvue Medical has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's Cyclically Adjusted Revenue per Share compare to BTCY and VYCO?
ENvue Medical's Cyclically Adjusted Revenue per Share of €356.84 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ENvue Medical and its competitors. ENvue Medical's current Cyclically Adjusted Revenue per Share is €356.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
ENvue Medical (FRA:56R1) has a current Cyclically Adjusted Revenue per Share of €356.84. The stock's GF Value™ is €72.47, compared to a current price of €6.20 — trading 91.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €356.84. ENvue Medical's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ENvue Medical (FRA:56R1), the current Cyclically Adjusted Revenue per Share is €356.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ENvue Medical (FRA:56R1) Overvalued in 2026?

Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued. The current stock price of €6.20 is trading 91.4% below its estimated GF Value™ of €72.47.

Key valuation signals for FRA:56R1:

  • Cyclically Adjusted Revenue per Share: €356.84
  • GF Value™: €72.47 vs. price of €6.20 (91.4% below fair value)
  • GF Score™: 37/100 with 4 warning signs

No single metric tells the full story. See the FRA:56R1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ENvue Medical Business Description

Other Exchanges FEED:USA
Address 969 Pruitt Avenue, Tyler, TX, USA, 77569
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
37GF Score

Get the complete analysis for FRA:56R1

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.20
Price
€72.47
GF Value